Table 2

Infusion products and clinical responses

Patient nrTIL characteristicsPhenotypeReactivity against autologous tumorClinical results
*cells (x1010)Culture time% CD8+% CD4+% PD1+% CCR7+% CD27+% CD28+% CD45RA+% CD62L+% IFN-γ% TNF-α% IL-2# IL-2ResultSurvival
Pre-REP TILOf total CD8+ or CD4+*Infusions
No clinical benefit
 112.02191.1CD8+22.43.95.145.78.63.90,19†ndnd9PD17 mo
1.3CD4+19.78.45.51.817.98.4ndndnd
 29.81832.1CD8+26.42.11.450.510.922.514.25.21.13SD (2 mo)7 mo
64.1CD4+30.62.92.21.22.214.41.46.20.2
 615.01469.0CD8+23.72.22.055.24.213.81.60.40.24PD2 mo
19.6CD4+11.82.12.63.24.84.62.10.50.8
 914.91994.9CD8+13.01.42.332.92.23.710.80.70.52PD2 mo
3.0CD4+13.75.95.72.18.27.94.05.50.0
 101.71537.6CD8+64.95.52.926.196.51.45.80.90.46PD1.5 mo
55.9CD4+56.14.14.20.798.31.313.023.27.7
Clinical benefits
 319.61879.4CD8+47.84.74.643.52.47.119.4ndnd4CR
(108 mo+)
108 mo+
6.2CD4+23.25.66.53.26.87.2ndndnd
 47.01825.4CD8+6.64.13.650.07.421.74.13.30.92PR (6 mo)16 mo
57.0CD4+7.85.33.51.74.314.61.72.51.4
 518.91795.8CD8+2.81.42.75.50.40.59.5ndnd2PR (6 mo)24 mo
1.0CD4+20.57.56.82.51.93.1ndndnd
 713.91681.4CD8+6.912.37.449.757.450.40.30.00.04PR (5 mo)42 mo
10.4CD4+5.798.157.427.2220.2738.470.12.20.2
 814.71160.4CD8+13.39.515.321.221.55.014.38.53.71CR
(84 mo+)
84 mo+
19.3CD4+11.67.013.91.412.53.81.41.00.1
  • *Background levels of cytokine production by T cells cultured without tumor material was subtracted.

  • †No autologous tumor line or digest available. Reactivity of infusion TIL tested against partly HLA matched melanoma cell line nd=not determined.

  • CR, complete remissions; IFN-γ, interferon-γ; mo, month; PR, partial response; TIL, tumor infiltrating lymphocyte; TNF-α, tumor necrosis factor α.